Benefits of the venous thrombo embolism (VTE) drug apixaban when compared to its leading rival Sanofi-aventi's enoxaparin have been published by the staff in clinical research jobs at Pfizer and Bristol-Myers Squibb (BMS). Apixaban has been developed as part of a global collaborative agreement signed by Pfizer and BMS in 2007.
Apixaban, which is administered orally, outperformed enoxaparin in reducing the incidence of venous thrombo embolism (VTE) among patients undergoing elective total hip replacement surgery.
Lead investigator of the study, Dr Michael Rud Lassen of the Hoersholm
Hospital in Copenhagen said, "This is encouraging, as the risk of bleeding is a key concern for orthopedic surgeons using oral anticoagulants." In August 2010, clinical data had been published that assessed the effectiveness of apixaban as compared to aspirin, in preventing strokes among atrial fibrillation patients.